
https://www.science.org/content/blog-post/glioblastoma-vaccine-not-yet
# A Glioblastoma Vaccine? Not Yet. (May 2018)

## 1. SUMMARY  
The article critiques the hype surrounding DCVax‑L, a dendritic‑cell vaccine for glioblastoma developed by Northwest Biotherapeutics (NWBO). It points out a decade‑long series of regulatory holds, enrollment shortfalls, financial turmoil, and opaque data reporting that have plagued the program. The author notes that the trial’s crossover design means ~90 % of participants eventually receive the vaccine, making any comparison to standard of care difficult. At the time of writing, only an interim, still‑blinded analysis had been published, and the company warned that definitive overall‑survival results would not be available until later in the summer of 2018. The piece concludes that, given the company’s track record and the aggressive nature of glioblastoma, optimism should be tempered.

## 2. HISTORY  
**Post‑2018 trial data** – In October 2021, Northwest Biotherapeutics released a peer‑reviewed paper reporting overall‑survival (OS) results from the DCVax‑L trial in newly diagnosed glioblastoma. The single‑arm study (with a historical control) showed a median OS of **23.1 months** for the intent‑to‑treat population, compared with an external benchmark of ~15.9 months. Sub‑analyses suggested longer survival for patients with methylated MGMT promoter.  

**Regulatory status** – Despite the 2021 publication, the U.S. FDA has **not granted approval** for DCVax‑L. The agency has requested additional data, particularly a randomized controlled trial (RCT) to confirm efficacy and safety. As of early 2024, the vaccine remains investigational and is only available through clinical‑trial enrollment.  

**Company trajectory** – NWBO was delisted from NASDAQ in 2015 and now trades on the OTC market under the ticker “NWBO”. The 2021 data caused a modest, short‑lived uptick in the share price, but the company’s market capitalization remains in the low‑hundreds of millions. Funding has continued through private placements and public offerings, but the firm has not secured a major pharmaceutical partner for commercialization.  

**Further clinical work** – In 2022 the company announced the start of a **Phase III‑style extension trial** (DCVax‑L + standard radiochemotherapy) for newly diagnosed patients, aiming to enroll several hundred participants. Enrollment has progressed slowly, and as of late 2023 the trial is still ongoing with no public efficacy readout.  

**Broader field** – Dendritic‑cell vaccines have not become a standard component of glioblastoma care. Other immunotherapy approaches (e.g., checkpoint inhibitors, CAR‑T cells) have also struggled to demonstrate clear survival benefit in large RCTs. The overall landscape for glioblastoma remains dominated by maximal surgical resection, temozolomide, and radiotherapy, with median survival still around 15–20 months for most patients.  

**Public perception** – The early 2018 British media hype faded after the 2021 results were released; mainstream coverage now treats DCVax‑L as an experimental therapy with uncertain regulatory prospects rather than a breakthrough.

## 3. PREDICTIONS  
- **Prediction:** *“The vaccine will not be ready for patients any time soon; data will be delayed.”*  
  **Outcome:** Accurate. Definitive OS data did not appear until late 2021, and FDA approval remains pending as of 2024.  

- **Prediction:** *“Northwest Biotherapeutics has struggled to explain trial delays and enrollment shortfalls.”*  
  **Outcome:** Confirmed. The company continued to cite enrollment challenges and regulatory holds through 2022‑2023, and external observers have repeatedly noted the lack of transparent trial timelines.  

- **Prediction (implicit):** *“The dendritic‑cell vaccine concept has a poor track record and is unlikely to become widely adopted.”*  
  **Outcome:** Largely correct. Apart from DCVax‑L, no dendritic‑cell vaccine has achieved regulatory approval for any solid tumor, and the approach remains niche.  

- **Prediction:** *“The crossover design will make efficacy assessment difficult.”*  
  **Outcome:** True. The 2021 analysis relied on historical controls rather than a concurrent control arm, and critics have highlighted the methodological limitations this imposes.  

- **Prediction:** *“The company will not secure a major partnership or blockbuster revenue.”*  
  **Outcome:** Accurate. NWBO remains independent, with modest financing and no licensing deal that would generate large revenues.  

## 4. INTEREST  
**Rating: 6/10** – The article is a useful case study of how media hype can outpace scientific reality and illustrates the challenges of translating dendritic‑cell vaccines into approved therapies, but the underlying story has not dramatically altered the broader glioblastoma treatment landscape.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20180530-glioblastoma-vaccine-not-yet.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_